140 related articles for article (PubMed ID: 36130819)
1. Primary resection of oligometastatic recurrent prostatic carcinoma in the urethra.
Foo MA; Lim EJ; Cheng CWS; Ng LG
BMJ Case Rep; 2022 Sep; 15(9):. PubMed ID: 36130819
[TBL] [Abstract][Full Text] [Related]
2. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
[TBL] [Abstract][Full Text] [Related]
4. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
[TBL] [Abstract][Full Text] [Related]
5. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
[TBL] [Abstract][Full Text] [Related]
6. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
9. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
11. Perineal salvage prostatectomy for radiation resistant prostate cancer.
van der Poel HG; Beetsma DB; van Boven H; Horenblas S
Eur Urol; 2007 Jun; 51(6):1565-71; discussion 1572. PubMed ID: 16949728
[TBL] [Abstract][Full Text] [Related]
12. Does seminal vesicle-sparing robotic radical prostatectomy influence postoperative prostate-specific antigen measured with an ultrasensitive immunoassay?
Burkhardt O; Neuenschwander JE; John H; Randazzo M
Swiss Med Wkly; 2018 Nov; 148():w14685. PubMed ID: 30474852
[TBL] [Abstract][Full Text] [Related]
13. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
14. Prostate Specific Antigen Nadir After Radical Cystoprostatectomy in Patients With Benign Prostatic Tissue: A Benchmark To Define Biochemical Recurrence after Radical Prostatectomy.
Hosseini SY; Alemi M; Amini E; Riazi N
Urol J; 2019 Dec; 16(6):563-566. PubMed ID: 31004342
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience.
Liauw SL; Webster WS; Pistenmaa DA; Roehrborn CG
Urology; 2003 Jun; 61(6):1204-10. PubMed ID: 12809898
[TBL] [Abstract][Full Text] [Related]
17. Robot-assisted Placement of Pelvic Tissue Expander for Radiation After Prostatectomy and Cystectomy for Treatment of Prostate Cancer Biochemical Recurrence.
Quarrier SO; Matloubieh JE; Wu G
Urology; 2019 Feb; 124():292-296. PubMed ID: 30385261
[TBL] [Abstract][Full Text] [Related]
18. Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage.
Maitre P; Sood S; Pathare P; Krishnatry R; Agrawal A; Rangarajan V; Murthy V
Radiother Oncol; 2022 Apr; 169():71-76. PubMed ID: 35189154
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
20. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
